CALGB 9665: The CALGB Leukemia Tissue Bank
This study is for patients planning on being treated on a CALGB study for leukemia or myelodysplasia. Researchers from the Cancer and Leukemia Group B (CALGB) are attempting to better understand the causes of leukemia and myelodysplasia, and to develop improved methods for the diagnosis and treatment of these diseases. This study will allow the preservation and storage of a small portion of blood, bone marrow, and swabs of cells from the inside of the mouth from patients with these diseases. These materials will be used for the study of leukemia or myelodysplasia. In particular, the researchers are interested in studying particular molecules in the blood, bone marrow, and cheek cells. The exact molecules to be studied will change over time, and only the most promising will be chosen for investigation.
A Phase 2 Open-Label Study of the Efficacy of ABT 199 (GDC-0199) in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia Harboring the 17p Deletion
This is a A Phase 2 Open-Label Study conducted to measure the Efficacy of ABT-199 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia in subjects who have the 17p ( a gene) Deletion.
The purpose of this study is to evaluate the efficacy (how well the study drug works) of ABT-199 monotherapy in subjects with relapsed or refractory chronic lymphocytic leukemia (CLL) who have 17p deletion. The safety and tolerability of ABT-199 will also be evaluated. In addition, substances found in the blood, bone marrow and tissue (biomarkers) that may indicate the effects or progress of the leukemia and the activity of ABT-199 will be studied. Pharmacokinetics (how much ABT 199 is absorbed in your body at different times), pharmacogenetics (genetic differences that can affect individual responses to ABT-199) will also be evaluated.
NCI PROTOCOL #9540: A Phase I Study of Lenalidomide and Ibrutinib in Combination with Rituximab in Relapsed and Refractory CLL and SLL
This study is for subjects diagnosed with recurrent or relapsed CLL/SLL. The purpose of this study is to test the safety of the combination of the drugs lenalidomide and ibrutinib at different dose levels, in combination with the drug rituximab. We want to find out what effects, good and/or bad, they have on you and your CLL/SLL.
A Phase 2 Open-Label study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia Subjects with Relapse or Refractory to B-cell Receptor Signaling Pathway Inhibitor Therapy
This study is for patients who have relapsed (cancer has come back) or refractory (no response) chronic lymphocytic leukemia (CLL) after treatment.
The purpose of this study is to evaluate how well the study drug works and the safety of ABT-199 as a single agent in subjects with CLL who have relapsed after or are refractory to treatment with the drugs Ibrutinib and/or Idelalisib.
All patients on this study will take ABT-199 as a pill once a day for up to two years as long as they can tolerate the drug and have no evidence of disease progression.